Stereotaxis Market Leadership Reinforced in Core Curriculum and Symposium Presentations at Heart R...(by the enthusiastic reception our Niobe ...),Health

Date:5/20/2008

by the enthusiastic reception our Niobe and Odyssey systems received on the conference floor. We believe the conference further underlined the effectiveness of our technology in all four chambers of the heart. With our reputation for safety, simplicity and efficacy reinforced by this extremely successful event, we look forward to our goal of achieving 150 installations and a total of 25,000-30,000 procedures since inception, completed by Heart Rhythm 2009."

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe and Canada.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company's products in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company's periodic and other filings with the
'/>"/>

SOURCE Stereotaxis, Inc. Copyright©2008 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4
Related medicine technology :

1. CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence
2. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
3. FDA Grants Market Clearance for the LipiScan(TM) Coronary Imaging System Developed by InfraReDx, Inc. - A Novel Spectroscopy System for the Identification of Lipid Core Containing Plaques of Interest in the Coronary Arteries
4. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
5. Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market
6. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
7. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
8. Rapid Growth of Asia-Pacific Clinical Trials Market Focus of New CenterWatch Report
9. Successful Clinical Trials and Launch in New Zealand Spurs Phloe to Enter US Market
10. Infant Formula Manufacturers Again under Ethical Cloud: Marketing Gimmick Linked to Serious Illnesses
11. Clinical Trial Best Practices: Savvy Marketers Plan Ahead with Early Communication Strategies